Yosef Landesman
Cancer Clinic(US)
Publications by Year
Research Areas
Nuclear Structure and Function, Cancer-related Molecular Pathways, RNA Research and Splicing, Cancer, Lipids, and Metabolism, Acute Myeloid Leukemia Research
Most-Cited Works
- → Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma(2019)662 cited
- → Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial(2020)329 cited
- → CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications(2013)302 cited
- → First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors(2016)246 cited
- → XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer(2016)208 cited
- → Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias(2013)145 cited
- → Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing(2015)133 cited
- → Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death(2016)129 cited
- → Clinical translation of nuclear export inhibitors in cancer(2014)128 cited
- → KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells(2016)121 cited